Drug intelligence / Profile preview

gentamicin + metronidazole

Development stage
Phase 3
Lead developer
Schering Corporation and Rhône-Poulenc
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Oral, Topical, Rectal
01

Overview

Gentamicin + metronidazole is a combination of two antibiotics used primarily for the prevention and treatment of mixed aerobic and anaerobic bacterial infections, especially in surgical settings such as abdominal or gynecological procedures. Gentamicin is an aminoglycoside antibiotic that acts by binding to the 30S ribosomal subunit, inhibiting protein synthesis in susceptible Gram-negative bacteria. Metronidazole is a nitroimidazole antibiotic effective against most anaerobic bacteria and certain protozoa; it works by disrupting DNA synthesis after reduction within anaerobic cells. The combination provides broad-spectrum coverage against both aerobic (gentamicin) and anaerobic (metronidazole) pathogens, making it particularly useful for prophylaxis in surgeries with high risk of contamination or infection involving both types of organisms[1][2][5]. Clinical studies have shown that this combination can be more effective than either agent alone for preventing post-surgical infections, including intra-abdominal abscesses and post-caesarean wound infections[1][2][4].

02

Targets

Bacterial RibosomeNeuraminidase

Beyond the preview

Go deeper on gentamicin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gentamicin + metronidazole.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call